Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review.

Sriram S, Arnolda L

Therapeutic advances in drug safety16 May 2026

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Semaglutide.

  1. 01HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In a man with 26 kg of weight loss on semaglutide and long-term nicotine replacement, acute heart failure with dilated cardiomyopathy and an ejection fraction of 15% occurred; the authors think energy deficit, not direct drug toxicity, contributed.

    In plain wordsOne man on semaglutide and long-term nicotine replacement had severe heart failure after fast weight loss; the cause cannot be tied to semaglutide alone.

    Outcome
    Not applicableDilated cardiomyopathy with heart failure
    Study

    n = 1

    Outcome group
    Adverse events · Cardiovascular

    Source sentences

    Summary
    Evaluation showed global left ventricular systolic dysfunction with an ejection fraction of 15%, marked dilation, moderate mitral regurgitation and right ventricular insertion-point fibrosis.
    2 context sentences
    Summary · context
    Pharmacological exposures, such as glucagon-like peptide-1 agonists and chronic NRT, may have contributed indirectly by facilitating prolonged energy imbalance rather than acting as direct cardiotoxic agents.
    Summary · context
    He had intentionally lost 26 kg over 2 months through 0.25 mg semaglutide therapy, and reports >25 years of chronic nicotine replacement therapy (NRT: 30-40 mg/day).

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.